Opko Health (OPK) Reports Fiscal Q2 2025 Results

Opko Health Inc. (NASDAQ:OPK) is one of the best strong buy penny stocks to buy now. On July 31, Opko Health Inc. (NASDAQ:OPK) reported its fiscal Q2 2025 results, with consolidated total revenues for the quarter reaching $156.8 million compared to $182.2 million in the same quarter last year.

Operating loss for the quarter was $60.0 million, down from $61.7 million in Q2 2024.

Revenue from products in its Pharmaceuticals segment underwent a slight growth to $40.7 million in Q2 2025 from $40.5 million in Q2 2024, reflecting increased sales volumes in certain international operations. These trends were partially offset by lowered sales in its Chilean subsidiary, primarily due to a mild winter cold and flu season and foreign currency impacts.

Revenue from services in the diagnostics segment dropped to $101.1 million in Q2 2025 compared to $129.4 million in the prior year period. Management attributed the decrease to lower clinical test volume principally as a result of the sale of certain BioReference assets.

Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.

While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.